Logo image of ALTS

ALT5 SIGMA CORP (ALTS) Stock Fundamental Analysis

NASDAQ:ALTS - Nasdaq - US47089W1045 - Common Stock - Currency: USD

5.13  -0.15 (-2.84%)

Fundamental Rating

1

Taking everything into account, ALTS scores 1 out of 10 in our fundamental rating. ALTS was compared to 192 industry peers in the Pharmaceuticals industry. ALTS may be in some trouble as it scores bad on both profitability and health. ALTS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALTS had negative earnings in the past year.
ALTS had a positive operating cash flow in the past year.
In the past 5 years ALTS reported 4 times negative net income.
In the past 5 years ALTS reported 4 times negative operating cash flow.
ALTS Yearly Net Income VS EBIT VS OCF VS FCFALTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M -15M

1.2 Ratios

ALTS has a Return On Assets (-26.95%) which is in line with its industry peers.
ALTS has a Return On Equity (-83.81%) which is in line with its industry peers.
Industry RankSector Rank
ROA -26.95%
ROE -83.81%
ROIC N/A
ROA(3y)-43.38%
ROA(5y)-41.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTS Yearly ROA, ROE, ROICALTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 48.65%, ALTS is in the better half of the industry, outperforming 61.46% of the companies in the same industry.
ALTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALTS Yearly Profit, Operating, Gross MarginsALTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

More info and screens

3

2. Health

2.1 Basic Checks

ALTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALTS has more shares outstanding
The number of shares outstanding for ALTS has been increased compared to 5 years ago.
Compared to 1 year ago, ALTS has a worse debt to assets ratio.
ALTS Yearly Shares OutstandingALTS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
ALTS Yearly Total Debt VS Total AssetsALTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -0.55, we must say that ALTS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.55, ALTS perfoms like the industry average, outperforming 51.04% of the companies in the same industry.
The Debt to FCF ratio of ALTS is 3.36, which is a good value as it means it would take ALTS, 3.36 years of fcf income to pay off all of its debts.
ALTS has a Debt to FCF ratio of 3.36. This is amongst the best in the industry. ALTS outperforms 90.10% of its industry peers.
ALTS has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.32, ALTS perfoms like the industry average, outperforming 40.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF 3.36
Altman-Z -0.55
ROIC/WACCN/A
WACC10.01%
ALTS Yearly LT Debt VS Equity VS FCFALTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M 20M

2.3 Liquidity

ALTS has a Current Ratio of 0.75. This is a bad value and indicates that ALTS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.75, ALTS is doing worse than 89.58% of the companies in the same industry.
A Quick Ratio of 0.75 indicates that ALTS may have some problems paying its short term obligations.
With a Quick ratio value of 0.75, ALTS is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.75
ALTS Yearly Current Assets VS Current LiabilitesALTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ALTS have decreased strongly by -196.59% in the last year.
Looking at the last year, ALTS shows a very negative growth in Revenue. The Revenue has decreased by -77.08% in the last year.
EPS 1Y (TTM)-196.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.46%
Revenue 1Y (TTM)-77.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALTS Yearly Revenue VS EstimatesALTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
ALTS Yearly EPS VS EstimatesALTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALTS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTS Price Earnings VS Forward Price EarningsALTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALTS indicates a rather cheap valuation: ALTS is cheaper than 84.90% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 21.74
EV/EBITDA N/A
ALTS Per share dataALTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALT5 SIGMA CORP

NASDAQ:ALTS (3/7/2025, 8:04:39 PM)

5.13

-0.15 (-2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12
Earnings (Next)04-07 2025-04-07
Inst Owners7.03%
Inst Owner Change0%
Ins Owners5.38%
Ins Owner Change23.08%
Market Cap72.18M
Analysts0
Price TargetN/A
Short Float %1.77%
Short Ratio0.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.15
P/FCF 21.74
P/OCF 21.74
P/B 3
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.92
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.24
FCFY4.6%
OCF(TTM)0.24
OCFY4.6%
SpS0.51
BVpS1.71
TBVpS-1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.95%
ROE -83.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.65%
FCFM 46.69%
ROA(3y)-43.38%
ROA(5y)-41.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF 3.36
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.75
Altman-Z -0.55
F-Score4
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-196.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.46%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-77.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-97.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y163.12%
FCF growth 3YN/A
FCF growth 5Y-17.16%
OCF growth 1Y179.24%
OCF growth 3YN/A
OCF growth 5Y-18.82%